S-GLYN Trademark

Trademark Overview


On Friday, May 10, 2024, a trademark application was filed for S-GLYN with the United States Patent and Trademark Office. The USPTO has given the S-GLYN trademark a serial number of 79404587. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Wednesday, August 13, 2025. This trademark is owned by Samsung Biologics Co., Ltd.. The S-GLYN trademark is filed in the Treatment & Processing of Materials Services and Computer & Software Services & Scientific Services categories with the following description:

Custom manufacture of biopharmaceuticals; processing of biopharmaceutical materials for others; treatment of biopharmaceutical materials; custom manufacture of cell lines for manufacturing biopharmaceuticals; chemical treatment of liquids; processing of medicinal materials; custom manufacture of pharmaceuticals; processing of pharmaceutical preparations; preservation of pharmaceuticals; processing of pharmaceuticals; custom manufacture of specific antibody-binding glycosylation drugs; processing of chemicals.

scientific laboratory service for high-efficiency glycan analysis; culturing of cells for scientific research purposes; scientific research; biological research and analysis relating to glycosylation profiles; multiple nucleic acid analysis; protein analysis; toxicity analysis; scientific research in the field of molecular analysis; development of biotechnology; biotechnological research; scientific research in the field of biological analysis; biological research; scientific research in the field of biologics; scientific research in the field of biochemical analysis; biochemical research; food research; conducting early evaluations in the field of new pharmaceuticals; drug discovery services; development of pharmaceutical preparations and medicines; pharmaceutical research and development; research on the subject of pharmaceuticals; pharmaceutical product evaluation; clinical research in the field of medicine; testing services for assessing the efficiency of pharmaceuticals; scientifi...

General Information


Serial Number79404587
Word MarkS-GLYN
Filing DateFriday, May 10, 2024
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateWednesday, August 13, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing5 - Drawing with word(s) / letter(s) / number(s) in Stylized form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesCustom manufacture of biopharmaceuticals; processing of biopharmaceutical materials for others; treatment of biopharmaceutical materials; custom manufacture of cell lines for manufacturing biopharmaceuticals; chemical treatment of liquids; processing of medicinal materials; custom manufacture of pharmaceuticals; processing of pharmaceutical preparations; preservation of pharmaceuticals; processing of pharmaceuticals; custom manufacture of specific antibody-binding glycosylation drugs; processing of chemicals.
Description of MarkThe mark consists of the stylized wording "S-GLYN".
Goods and Servicesscientific laboratory service for high-efficiency glycan analysis; culturing of cells for scientific research purposes; scientific research; biological research and analysis relating to glycosylation profiles; multiple nucleic acid analysis; protein analysis; toxicity analysis; scientific research in the field of molecular analysis; development of biotechnology; biotechnological research; scientific research in the field of biological analysis; biological research; scientific research in the field of biologics; scientific research in the field of biochemical analysis; biochemical research; food research; conducting early evaluations in the field of new pharmaceuticals; drug discovery services; development of pharmaceutical preparations and medicines; pharmaceutical research and development; research on the subject of pharmaceuticals; pharmaceutical product evaluation; clinical research in the field of medicine; testing services for assessing the efficiency of pharmaceuticals; scientific research in the field of genetics and genetic engineering; scientific research in the field of genetics and genetic engineering; computer programming in the medical field; medical research laboratories; computer project management services relating to imaging medical data; medicine research; analysis and evaluation of medical product development; providing information on the testing, inspection and research of medical products; providing medical and scientific research information in the field of clinical trial progress; scientific research in the nature of conducting clinical trials for others

Classification Information


International Class040 - Treatment of materials.
US Class Codes100, 103, 106
Class Status Code6 - Active
Class Status DateThursday, September 19, 2024
Primary Code040
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, September 19, 2024
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameSamsung Biologics Co., Ltd.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressKR

Trademark Events


Event DateEvent Description
Thursday, September 19, 2024SN ASSIGNED FOR SECT 66A APPL FROM IB
Thursday, September 19, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sunday, November 24, 2024ASSIGNED TO EXAMINER
Thursday, September 19, 2024APPLICATION FILING RECEIPT MAILED
Thursday, March 13, 2025NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Friday, May 9, 2025REFUSAL PROCESSED BY IB
Wednesday, March 12, 2025NON-FINAL ACTION WRITTEN
Wednesday, April 23, 2025NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Wednesday, April 23, 2025REFUSAL PROCESSED BY MPU
Wednesday, August 13, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, August 13, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, August 13, 2025TEAS/EMAIL CORRESPONDENCE ENTERED